Rinderon

Rinderon Brand names, Rinderon Analogs

Rinderon Brand Names Mixture

Lotrisone (betamethasone + clotrimazole)

Rinderon Chemical_Formula

C₂₂H₂₉FO₅

Rinderon RX_link

http://www.rxlist.com/cgi/generic2/betamet.htm

Rinderon fda sheet

Rinderon FDA

Rinderon msds (material safety sheet)

Rinderon MSDS

Rinderon Synthesis Reference

Taub et al., J. Am. Chem. Soc. 80, 4435 (1958)

Rinderon Molecular Weight

392.461 g/mol

Rinderon Melting Point

231-234^oC

Rinderon H₂O Solubility

Insoluble

Rinderon State

Solid

Rinderon LogP

1.772

Rinderon Dosage Forms

Oral Solution; Tablet; Solution for Injection; Injectable Suspension; Cream; Gel; Ointment; Foam; Lotion

Rinderon Indication

Topical use (cream, lotion and ointment): for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses
Topical use (foam): relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp
Systemic use: for the treatment of edocrine disorders, rheumatic disorders, collagen diseases, dermatological diseases, allergic states, ophthalmic diseases, respiratory diseases, hematologic disorders, neoplastic diseases, edematous states, gastrointestinal diseases, tuberculous meningitis and trichinosis.

Rinderon Pharmacology

Betamethasone and its derivatives, betamethasone sodium phosphate and betamethasone acetate, are synthetic glucocorticoids. Used for its antiinflammatory or immunosuppressive properties, betamethasone is combined with a mineralocorticoid to manage adrenal insufficiency and is used in the form of betamethasone benzoate, betamethasone dipropionate, or betamethasone valerate for the treatment of inflammation due to corticosteroid-responsive dermatoses. Betamethasone and clotrimazole are used together to treat cutaneous tinea infections.

Rinderon Absorption

Minimal if applied topically.

Rinderon side effects and Toxicity

Symptoms of overdose include burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.

Rinderon Patient Information

Patients using topical corticosteroids should receive the following information and instructions. This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.

1. This medication is to be used as directed by the physician and should not be used longer than the prescribed time period. It is for external use only. Avoid contact with the eyes.

2. Patients should be advised not to use this medication for any disorder other than that for which it was prescribed.

3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive.

4. Patients should report any signs of local adverse reactions.

5. Other corticosteroid-containing products should not be used with DIPROLENE AF Cream without first talking to your physician.

Rinderon Organisms Affected

Humans and other mammals